{"product_id":"bsx-ansoff-matrix","title":"Boston Scientific Corporation (BSX): Ansoff Matrix [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Boston Scientific Corporation Business analysis gives you a clear, research-based growth strategy map covering market penetration, market development, product development, and diversification. You'll see how the company can push FARAPULSE, WATCHMAN FLX, and OPAL; expand into China, EMEA, and Asia-Pacific; advance Valencia eCoin, MiRus TAVR, SEISMIQ, and Nalu; and weigh key risks around regulation, clinical evidence, execution, and targeted M\u0026amp;A.\u003c\/p\u003e\u003ch2\u003eBoston Scientific Corporation - Ansoff Matrix: Market Penetration\u003c\/h2\u003e\n\u003cp\u003eBoston Scientific Corporation's market penetration case rests on existing U.S. accounts, existing specialties, and more procedure volume inside those accounts. The main real-life anchors are \u003cstrong\u003e$16.75 billion\u003c\/strong\u003e in 2024 net sales, \u003cstrong\u003e2024\u003c\/strong\u003e U.S. FDA approval for FARAPULSE, and \u003cstrong\u003e3,165\u003c\/strong\u003e patients in CHAMPION-AF.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eExpand FARAPULSE U.S. launch execution\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFARAPULSE turned Boston Scientific Corporation's electrophysiology push into a penetration move because it entered the same hospitals, EP labs, and physician groups that already buy ablation tools. FDA approval in \u003cstrong\u003e2024\u003c\/strong\u003e lets the company sell into the same customer base instead of building a new one, so each added lab and each added ablation case increases share inside a familiar account.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e U.S. FDA approval.\u003c\/li\u003e\n\u003cli\u003eSame EP account base.\u003c\/li\u003e\n\u003cli\u003eMore procedure volume in existing labs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eConvert CHAMPION-AF data into WATCHMAN FLX share gains\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCHAMPION-AF enrolled \u003cstrong\u003e3,165\u003c\/strong\u003e patients, which makes it a direct commercial proof point for WATCHMAN FLX. In market penetration terms, the value is not a new geography or a new specialty; it is the ability to move more eligible atrial fibrillation patients inside the same cardiology and structural heart accounts.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eReal-life number or date\u003c\/th\u003e\n\u003cth\u003ePenetration use\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBoston Scientific Corporation\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$16.75 billion\u003c\/strong\u003e 2024 net sales\u003c\/td\u003e\n\u003ctd\u003eSales, training, and service support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFARAPULSE\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e U.S. FDA approval\u003c\/td\u003e\n\u003ctd\u003eExisting EP account expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCHAMPION-AF\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3,165\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eWATCHMAN FLX adoption support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEKOS evidence base\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e150\u003c\/strong\u003e, \u003cstrong\u003e59\u003c\/strong\u003e, and \u003cstrong\u003e101\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eInterventional account retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDeepen EP account penetration with OPAL mapping\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOPAL mapping strengthens penetration because mapping software and ablation hardware are bought together in the same EP workflow. Once a lab trains staff, sets inventory, and standardizes procedures around one workflow, the same account becomes harder to displace and easier to expand.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePush EKOS and Nalu through clinical evidence\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEKOS has a clear numeric evidence trail for penetration. The published study sizes tied to the platform include \u003cstrong\u003e150\u003c\/strong\u003e patients in SEATTLE II, \u003cstrong\u003e59\u003c\/strong\u003e in ULTIMA, and \u003cstrong\u003e101\u003c\/strong\u003e in PERFECT. Those numbers matter because clinical evidence is what supports repeat use inside the same interventional accounts. Nalu follows the same logic: clinical evidence has to move the buying committee inside the existing customer base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSEATTLE II: \u003cstrong\u003e150\u003c\/strong\u003e patients.\u003c\/li\u003e\n\u003cli\u003eULTIMA: \u003cstrong\u003e59\u003c\/strong\u003e patients.\u003c\/li\u003e\n\u003cli\u003ePERFECT: \u003cstrong\u003e101\u003c\/strong\u003e patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eUse efficiency gains to protect customer retention\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBoston Scientific Corporation's \u003cstrong\u003e$16.75 billion\u003c\/strong\u003e 2024 net sales base gives it room to protect retention through service, clinical support, and field coverage. In a penetration strategy, efficiency matters because the company does not need to buy new customers; it needs to keep the installed base active, trained, and buying more categories from the same sales team.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$16.75 billion\u003c\/strong\u003e 2024 net sales.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e approval-led launch cycle.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3,165\u003c\/strong\u003e-patient clinical evidence base for WATCHMAN FLX.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eBoston Scientific Corporation - Ansoff Matrix: Market Development\u003c\/h2\u003e\n\u003cp\u003eBoston Scientific Corporation's market development strategy depends on taking existing devices into more countries, more hospitals, and more distributor networks. The scale behind that approach shows up in \u003cstrong\u003e$16.747 billion\u003c\/strong\u003e of 2024 net sales.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMarket development lever\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eReal-life fact\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNumber or amount\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina expansion\u003c\/td\u003e\n\u003ctd\u003eDevice launch depends on approval from the National Medical Products Administration\u003c\/td\u003e\n \u003ctd\u003eNMPA\u003c\/td\u003e\n\u003ctd\u003eApproval turns one product into a national commercial opportunity\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFARAPULSE rollout\u003c\/td\u003e\n\u003ctd\u003eRegional scaling across Europe, the Middle East, Africa, and Asia-Pacific\u003c\/td\u003e\n \u003ctd\u003eEMEA, Asia-Pacific\u003c\/td\u003e\n\u003ctd\u003eLets Boston Scientific reuse the same platform across multiple countries\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWATCHMAN access\u003c\/td\u003e\n\u003ctd\u003eWorldwide patient experience with the device\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003e300,000+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupports adoption in more international implanting centers\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany scale\u003c\/td\u003e\n\u003ctd\u003eBoston Scientific reported 2024 net sales\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003e$16.747 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProvides the sales base needed to fund country launches and training\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eExpand OPAL in China after NMPA approval\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eChina market entry is tied to NMPA clearance. Once a product gets that approval, Boston Scientific can move from regulatory work into sales calls, physician training, and hospital procurement. That matters because China is not a single local market; it is a national launch that usually requires local evidence, local support, and local commercial execution.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eScale FARAPULSE across EMEA and Asia-Pacific\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFARAPULSE fits market development because the product does not need a redesign to enter more countries. The company can use the same device platform, the same training model, and the same clinical workflow across EMEA and Asia-Pacific. That lowers the cost of expansion compared with building a new product line for each region.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBroaden WATCHMAN access in more international centers\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWATCHMAN has been used in more than \u003cstrong\u003e300,000\u003c\/strong\u003e patients worldwide. More international centers matter because adoption in this category depends on physician training, referral flow, and procedural confidence. Each new center can add volume without Boston Scientific having to create a new device family.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eExtend interventional devices into new geographies\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGeographic expansion increases the number of patients and hospitals Boston Scientific can serve without changing the underlying device. That is the main market development logic in medtech: keep the product, then open new countries, new reimbursement systems, and new hospital networks.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eUse local distributors for MedSurg expansion\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal distributors matter in MedSurg because they can handle country-level procurement, logistics, and service coverage where a full direct sales force would be slower or more expensive. This channel is especially useful in fragmented markets where Boston Scientific needs local reach before it can justify a larger direct presence.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$16.747 billion\u003c\/strong\u003e shows the company has the revenue base to support international expansion.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e300,000+\u003c\/strong\u003e WATCHMAN patients show the installed base that can support more center-level adoption.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eNMPA\u003c\/strong\u003e approval is the key step for China commercialization.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eEMEA\u003c\/strong\u003e and \u003cstrong\u003eAsia-Pacific\u003c\/strong\u003e are the main regional blocks for scaling FARAPULSE.\u003c\/li\u003e\n \u003cli\u003eLocal distributors are the practical route for MedSurg in smaller or more fragmented markets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eBoston Scientific Corporation - Ansoff Matrix: Product Development\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e2024\u003c\/strong\u003e is the clearest product-development year to track in Boston Scientific because the company tied new-device growth to \u003cstrong\u003e$3.7 billion\u003c\/strong\u003e in OAB-related acquisition spend, \u003cstrong\u003e$1.16 billion\u003c\/strong\u003e in structural-heart acquisition spend, and \u003cstrong\u003eDecember 13, 2023\u003c\/strong\u003e FDA approval for FARAPULSE. The named programs in this chapter split into verified numerical milestones and items with no Boston Scientific public numeric disclosure.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct development lane\u003c\/th\u003e\n\u003cth\u003eReal-life numeric fact\u003c\/th\u003e\n\u003cth\u003eDate\u003c\/th\u003e\n\u003cth\u003eBoston Scientific relevance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOAB neuromodulation\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.7 billion\u003c\/strong\u003e; \u003cstrong\u003e$71.00\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFebruary 20, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAxonics acquisition closed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStructural heart expansion\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.16 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMay 1, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSilk Road Medical acquisition closed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElectrophysiology\u003c\/td\u003e\n\u003ctd\u003eFirst U.S.-approved PFA system\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDecember 13, 2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFARAPULSE FDA approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eFebruary 20, 2024\u003c\/strong\u003e - Axonics acquisition closed for \u003cstrong\u003e$3.7 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$71.00\u003c\/strong\u003e - cash consideration per Axonics share.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMay 1, 2024\u003c\/strong\u003e - Silk Road Medical acquisition closed for \u003cstrong\u003e$1.16 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDecember 13, 2023\u003c\/strong\u003e - FARAPULSE FDA approval.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e - U.S. commercial rollout period for FARAPULSE.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAdvance Valencia eCoin for overactive bladder\u003c\/strong\u003e sits in the same OAB and neuromodulation lane that Boston Scientific reinforced with the \u003cstrong\u003e$3.7 billion\u003c\/strong\u003e Axonics transaction closed on \u003cstrong\u003eFebruary 20, 2024\u003c\/strong\u003e. The hard number that matters here is the size of Boston Scientific's OAB commitment, not a separately disclosed Boston Scientific eCoin revenue, unit, or approval figure.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eProgress MiRus TAVR system integration\u003c\/strong\u003e has no Boston Scientific public numerical disclosure under the MiRus name in 2024 filings, so there is no verified approval count, launch count, or revenue line to report for that item.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTurn SEISMIQ trial success into launch readiness\u003c\/strong\u003e also has no Boston Scientific public patient count, endpoint percentage, or dollar amount disclosed under that trial name, so there is no verified numerical readout to attach here.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBuild on Nalu COMFORT data with new pain therapies\u003c\/strong\u003e likewise has no Boston Scientific-disclosed sample size, responder rate, or revenue figure under that name, so there is no verified number to report for this line.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAdd EP imaging and PFA accessory innovations\u003c\/strong\u003e has the strongest public number trail: \u003cstrong\u003eDecember 13, 2023\u003c\/strong\u003e FDA approval for FARAPULSE and \u003cstrong\u003e2024\u003c\/strong\u003e U.S. rollout. That gives Boston Scientific a real launch base for accessory development around catheters, mapping compatibility, and procedure workflow.\u003c\/p\u003e\u003ch2\u003eBoston Scientific Corporation - Ansoff Matrix: Diversification\u003c\/h2\u003e\n\n\u003cp\u003eBoston Scientific's diversification is best measured by disclosed deal values of \u003cstrong\u003e$435 million\u003c\/strong\u003e, \u003cstrong\u003e$465 million\u003c\/strong\u003e, \u003cstrong\u003e$4.2 billion\u003c\/strong\u003e, \u003cstrong\u003e$925 million\u003c\/strong\u003e plus up to \u003cstrong\u003e$300 million\u003c\/strong\u003e, \u003cstrong\u003e$1.75 billion\u003c\/strong\u003e, \u003cstrong\u003e$615 million\u003c\/strong\u003e, and \u003cstrong\u003e$3.7 billion\u003c\/strong\u003e. The company also sold its Neurovascular business for \u003cstrong\u003e$1.5 billion\u003c\/strong\u003e in 2011.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEnter structural heart through TAVR\u003c\/strong\u003e Boston Scientific entered TAVR in 2017 through Symetis for \u003cstrong\u003e$435 million\u003c\/strong\u003e. Symetis brought the ACURATE neo platform into the structural heart portfolio.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear\u003c\/td\u003e\n\u003ctd\u003eTransaction\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eCategory\u003c\/td\u003e\n\u003ctd\u003ePortfolio effect\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2011\u003c\/td\u003e\n\u003ctd\u003eNeurovascular business sale to Stryker\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNeurovascular\u003c\/td\u003e\n\u003ctd\u003eExit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2017\u003c\/td\u003e\n\u003ctd\u003eSymetis acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$435 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStructural heart\u003c\/td\u003e\n\u003ctd\u003eTAVR platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2019\u003c\/td\u003e\n\u003ctd\u003eVertiflex acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$465 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePain management\u003c\/td\u003e\n\u003ctd\u003eLumbar spinal stenosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2019\u003c\/td\u003e\n\u003ctd\u003eBTG acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInterventional medicine\u003c\/td\u003e\n\u003ctd\u003eExpanded adjacent medtech\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003ctd\u003ePreventice acquisition announced\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$925 million\u003c\/strong\u003e upfront, up to \u003cstrong\u003e$300 million\u003c\/strong\u003e contingent\u003c\/td\u003e\n\u003ctd\u003eCardiac monitoring\u003c\/td\u003e\n\u003ctd\u003eAmbulatory diagnostics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003eBaylis Medical acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.75 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStructural heart access\u003c\/td\u003e\n\u003ctd\u003eTransseptal access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eAxonics acquisition announced\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUrology neuromodulation\u003c\/td\u003e\n\u003ctd\u003eSacral neuromodulation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eApollo Endosurgery acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$615 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEndoluminal surgery\u003c\/td\u003e\n\u003ctd\u003eGI and obesity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eEnter urology neuromodulation through eCoin\u003c\/strong\u003e Boston Scientific did not disclose an eCoin acquisition. The disclosed urology neuromodulation transaction was Axonics for \u003cstrong\u003e$3.7 billion\u003c\/strong\u003e, announced in 2023 and closed in 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEnter neurovascular thrombectomy through Penumbra\u003c\/strong\u003e Boston Scientific did not disclose a Penumbra acquisition. Its disclosed neurovascular transaction was the sale of the Neurovascular business to Stryker for \u003cstrong\u003e$1.5 billion\u003c\/strong\u003e in 2011.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBroaden into new pain-management markets\u003c\/strong\u003e Boston Scientific acquired Vertiflex for \u003cstrong\u003e$465 million\u003c\/strong\u003e in 2019. Vertiflex added a minimally invasive treatment for lumbar spinal stenosis, a pain-related spine market.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.2 billion\u003c\/strong\u003e BTG acquisition in 2019\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$925 million\u003c\/strong\u003e upfront and up to \u003cstrong\u003e$300 million\u003c\/strong\u003e contingent for Preventice\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.75 billion\u003c\/strong\u003e Baylis Medical acquisition in 2022\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$615 million\u003c\/strong\u003e Apollo Endosurgery acquisition\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe disclosed amounts show a diversification pattern built on M\u0026amp;A in adjacent medtech categories rather than internal development alone. The largest transaction in this set is \u003cstrong\u003e$4.2 billion\u003c\/strong\u003e for BTG, and the smallest is \u003cstrong\u003e$435 million\u003c\/strong\u003e for Symetis.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45497901613205,"sku":"bsx-ansoff-matrix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/bsx-ansoff-matrix.png?v=1740154611","url":"https:\/\/dcf-model.com\/es\/products\/bsx-ansoff-matrix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}